换一批
换一批Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
第一作者：
Ikuya,Miki
第一单位：
Division of Diabetes, Digestive and Kidney Diseases, Department of Clinical Molecular Medicine, Kobe University School of Medicine, Kobe, Japan.
作者：
主题词
2-吡啶甲基亚硫酰苯咪唑类(2-Pyridinylmethylsulfinylbenzimidazoles);成年人(Adult);老年人(Aged);阿莫西林(Amoxicillin);抗菌药(Anti-Bacterial Agents);抗溃疡病药(Anti-Ulcer Agents);芳基烃羟化酶类(Aryl Hydrocarbon Hydroxylases);苯咪唑类(Benzimidazoles);克拉霉素(Clarithromycin);抗药性, 细菌(Drug Resistance, Bacterial);药物疗法, 联合(Drug Therapy, Combination);女(雌)性(Female);胃炎(Gastritis);螺杆菌感染(Helicobacter Infections);幽门螺杆菌(Helicobacter pylori);人类(Humans);Logistic模型(Logistic Models);男(雄)性(Male);中年人(Middle Aged);混合功能氧化酶类(Mixed Function Oxygenases);奥美拉唑(Omeprazole);消化性溃疡(Peptic Ulcer);多态现象, 遗传(Polymorphism, Genetic);质子泵抑制剂(Proton Pump Inhibitors);治疗失败(Treatment Failure);治疗结果(Treatment Outcome)
DOI
10.1097/00042737-200301000-00006
PMID
12544691
发布时间
2019-09-06
- 浏览18
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
